

#### **India I Equities**

# Building Material - Ceramics Company Update

Change in Estimates ☑ Target ☑ Reco □

24 November 2025

### **Cera Sanitaryware**

Soft performance; eyeing growth-oriented luxury segment; retaining BUY

Cera Sanitaryware reported a flat revenue of ~Rs4.9bn in Q2 FY26, largely due to subdued retail environment and poor performance of faucetware. Gross profit declined 3.7% y/y to ~Rs2.5bn, led by elevated input cost. Despite high employee expenses, decline in EBITDA was arrested at Rs671m (down 3.5% y/y), owing to lower other operating expenses. However, PAT tumbled 16.8% y/y to Rs566m due to one-time deferred tax income recognised in previous year. Management targets 10-12% growth in H2 FY26 and 7-8% growth in FY26. Expecting revenue/earnings to clock 8.9/11.8% CAGR over FY25-28, we maintain BUY rating on the stock with a 12-mth TP of Rs8,443 (from Rs8,956 earlier), valuing it at 35x FY27e/FY28e average EPS.

Muted revenue across key segments. While Sanitaryware/Tiles/Wellness revenue grew 1.4/3.1/3.2% y/y in Q2 FY26, Faucetware revenue fell 3.5% y/y due to high y/y base. Premium/mid/entry level products accounted for 42/36/22% of total sales. Tier-I/II/III cities accounted for 36/23/41% of total sales. While retail sales continue to face subdued demand, B2B (30% of total sales) reflect healthy traction.

Focus to enhance business in premium and entry segments. Cera is on track to achieve its FY26 flagship rollout target of 45-50 Senator Stores (28 stores already operational) along with expanding network for Polipluz to 100 distributors/2,000 dealers by Mar'26. The management targets Rs400-450m revenue in FY26 from Senator and Polipluz with a margin of 20-22/25% from FY27.

**Outlook.** Management is optimistic of recovery in H2 FY26 and aims at 7-8% growth in FY26. Volume recovery will aid achieving an operating margin of 14.5-15%. The company continues to focus on brand building, product innovation and operational efficiency. Expecting revenue/earnings to clock 8.9/11.8% CAGR over FY25-28, we maintain Buy rating on the stock with a downwardly revised 12-mth TP of Rs8,443 (from Rs8,956 earlier), valuing it at 35x FY27e/FY28e average EPS.

**Risks:** Demand slowdown, under-absorption of overheads, higher input cost, and increased competitive intensity.

FY24	FY25	FY26e	FY27e	FY28e
18,794	19,262	20,310	22,004	24,885
2,390	2,480	2,371	2,762	3,461
183.8	192.3	183.8	214.1	268.4
30.3	28.9	30.3	26.0	20.7
21.3	21.7	21.3	18.3	14.5
5.4	5.3	4.9	4.5	3.7
19.0	18.4	16.8	18.0	19.4
17.6	16.0	21.1	22.7	24.8
1.1	1.2	1.3	1.8	1.8
(0.6)	(0.5)	(0.5)	(0.5)	(0.6)
	18,794 2,390 183.8 30.3 21.3 5.4 19.0 17.6	18,794     19,262       2,390     2,480       183.8     192.3       30.3     28.9       21.3     21.7       5.4     5.3       19.0     18.4       17.6     16.0       1.1     1.2	18,794         19,262         20,310           2,390         2,480         2,371           183.8         192.3         183.8           30.3         28.9         30.3           21.3         21.7         21.3           5.4         5.3         4.9           19.0         18.4         16.8           17.6         16.0         21.1           1.1         1.2         1.3	18,794         19,262         20,310         22,004           2,390         2,480         2,371         2,762           183.8         192.3         183.8         214.1           30.3         28.9         30.3         26.0           21.3         21.7         21.3         18.3           5.4         5.3         4.9         4.5           19.0         18.4         16.8         18.0           17.6         16.0         21.1         22.7           1.1         1.2         1.3         1.8

Rating: **BUY**Target Price (12-mth): Rs.8,443
Share Price: Rs.5,566

Key Data	CRS IN / CERA.BO
52-week high / low	Rs8010 / 5062
Sensex / Nifty	85901 / 25960
Market cap	Rs73bn
Shares outstanding	13m

Shareholding Pattern (%)	Sep'25	Jun'25	Mar'25
Promoters	54.4	54.4	54.4
- of which, Pledged	-	-	-
Free float	45.6	45.6	45.6
- Foreign institutions	15.8	17.2	20.6
- Domestic institutions	13.6	12.1	6.9
- Public	16.2	16.3	18.1

Estimates Revision (%)	FY26e	FY27e	FY28e
Sales	(2.8)	(6.6)	(9.0)
EBITDA	(9.5)	(10.2)	(11.5)
PAT	(7.5)	(6.7)	(4.9)



Source: Bloomberg

Rishab Bothra Research Analyst

Anu Parakh Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

FY25

13,536

64

181

147

407

14,271

3,519

446

108

254

435

316

2,479

4,937

14,271

88

6,729

6

FY24

13,458

205

128

482

14,272

3.499

215

10

130

271

527

372

2,393

3,872

14,272

79

7,769

65

FY26e

14.617

162

188

407

15,374

3,769

446

6

75

254

6,729

1,152

2,486

5,043

15,374

386

64

FY27e

16.089

64

139

219

407

16.854

3,957

446

6

50

254

6,729

2,112

2,506

5,463

16,854

343

FY28e

19.550

64

117

219

407

20.293

4.082

446

6

25

254

6,729

299

4,821

2,547

6,179

20,293

Fig 2 - Balance sheet (Rs m)

### **Quick Glance – Financials and Valuations**

Y/E Mar

Net worth

Debt

Share capital

Minority interest

Capital employed

Net tangible assets


Not intangible accets

DTL / (Assets)

Fig 1 – Income State	ment (R	s m)			
Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Net revenue	18,794	19,262	20,310	22,004	24,885
Growth (%)	3.8	2.5	5.4	8.3	13.1
Direct cost	8,828	9,119	9,825	10,479	11,665
SG&A	6,934	7,144	7,470	8,086	9,060
EBITDA	3,033	2,998	3,015	3,438	4,160
EBITDA margin (%)	16.1	15.6	14.8	15.6	16.7
- Depreciation	365	407	413	413	428
Other income	595	605	698	825	1,089
Interest expenses	58	75	89	110	140
PBT	3,188	3,122	3,211	3,741	4,681
Effective tax rates (%)	24.3	19.9	25.0	25.0	25.0
+ Associates / (Minorities)	-23	-22	-38	-44	-50
Net income	2,390	2,480	2,371	2,762	3,461
Adj. income	2,390	2,480	2,371	2,762	3,461
WANS	13.0	12.9	12.9	12.9	12.9
FDEPS (Rs)	183.8	192.3	183.8	214.1	268.4
FDEPS growth (%)	14.1	4.6	-4.4	16.5	25.3
Gross margins (%)	53.0	52.7	51.6	52.4	53.1

089	Net intangible assets
140	Goodwill
681	CWIP (tang. & intang.)
25.0	Investments (strategic)
-50	Investments (financial)
461	Current assets (excl. cash)
461	Cash
2.9	Current liabilities
88.4	Working capital
25.3	Capital deployed
3.1	Contingent liabilities
	Fig 4 – Ratio Analys
′28e	Y/E Mar
681	P/E (x)
428	EV / EBITDA (x)
109	EV / Sales (x)
397)	P/B (x)
97) 118)	P/B (x) RoF (%)
	RoE (%)
)18)	

Fig 3 – Cash-flow Statement (Rs m)								
Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e			
PBT	3,188	3,122	3,211	3,741	4,681			
+ Non-cash items	365	407	413	413	428			
Oper. prof. before WC	3,554	3,529	3,624	4,153	5,109			
- Incr. / (decr.) in WC	67	(1,197)	(86)	(406)	(697)			
Others incl. taxes	(666)	(581)	(703)	(813)	(1,018)			
Operating cash-flow	2,955	1,751	2,835	2,935	3,394			
- Capex (tang. + intang.)	(655)	(633)	(629)	(575)	(528)			
Free cash-flow	2,300	1,118	2,206	2,360	2,866			
Acquisitions								
- Div. (incl. buyback & taxes)	(780)	(838)	(967)	(1,290)	(1,290)			
+ Equity raised	-	(1)	-	-	-			
+ Debt raised	(49)	(23)	(19)	(23)	(22)			
- Fin investments	(1,413)	1,058	-	-	-			
- Misc. (CFI + CFF)	52	(1,369)	(385)	(87)	1,154			
Net cash-flow	110	(55)	835	960	2,709			
Source: Company, Anand Rathi Res	earch							









Fig 6 - Revenue-mix



Source: Company, Anand Rathi Research

## Financial Highlights

(Rs m)	O4EV2E	O4EV26	O4EV26	(0/2		HALVOE	HATVOC		EV24	EVAE	(0/)
, ,	Q1FY25	Q1FY26	Q1FY26	y/y (%)	q/q (%)	H1FY25	H1FY26	y/y (%)	FY24	FY25	y/y (%)
Revenue	4,900	4,194	4,879	(0.4)	16.3	8,880	9,073	2.2	18,794	19,153	1.9
Raw material cost	2,330	1,981	2,403	3.2	21.3	4,134	4,384	6.1	8,828	9,096	3.0
Employee costs	627	645	652	4.1	1.1	1,207	1,298	7.5	2,309	2,415	6.2
Other expenses	1,248	1,038	1,152	(7.7)	11.0	2,282	2,190	(4.0)	4,624	4,734	1.,4
EBITDA	696	531	671	(3.5)	26.5	1,257	1,202	(4.4)	3,033	2,907	(1.1)
Other income	184	186	166	(9.8)	(10.9)	346	352	1.5	595	625	1.7
Depreciation	101	91	98	(3.1)	8.1	186	189	1.9	365	385	11.2
Finance costs	25	14	16	(35.2)	13.7	37	31	(16.5)	58	71	28.7
Profit/Loss from Associate	-	-	-	-	-	-	-	-	(16)	(15)	(3.3)
PBT	753	611	722	(4.1)	18.2	1,381	1,334	(3.4)	3,188	3,061	(2.6)
Tax	72	146	156	116.0	6.7	231	302	30.8	775	596	(20.0)
MI	-	-	-	-	-	-	-	-	23	-	(100.0)
PAT	681	465	566	(16.8)	21.7	1,150	1,032	(10.3)	2,390	2,465	3.1
EPS (Rs)	52.8	36.1	43.9	(16.8)	21.7	89.2	80.0	(10.3)	182.7	191.1	4.6
			,	y/y / (bps)	q/q / (bps)						bps / y/y
Gross margin	52.5	53.0	50.7	(172)	(203)	53.4	51.7	(177)	53.0	52.5	(52)
Employee cost	12.8	15.5	13.4	58	(201)	13.6	14.3	71	12.3	12.6	32
Other operating costs	25.5	24.5	23.6	(185)	(113)	25.7	24.1	(156)	24.6	24.7	11
EBITDA margins	14.2	12.7	13.8	(44)	111	14.2	13.2	(91)	16.1	15.2	(96)
Other income	3.7	4.3	3.4	(35)	(104)	3.9	3.9	(3)	3.2	3.3	10
Depreciation	2.1	2.3	2.0	(6)	(15)	2.1	2.1	(0)	1.9	2.0	7
Interest expenses	0.5	0.4	0.3	(18)	(1)	0.4	0.3	(8)	0.3	0.4	6
PBT	15.4	14.7	14.8	(56)	23	15.6	14.7	(86)	17.0	16.0	(98)
Tax rates	9.6	24.3	21.6	1,199	(231)	16.7	22.6	592	24.3	19.5	(484)
PAT margins	13.9	11.0	11.6	(228)	52	13.0	11.4	(158)	12.7	12.9	15

### **Q2 FY26 – Results Analysis**

#### Soft performance with muted revenues/ lower profitability

- Revenue at  $\sim$ Rs4.9bn was marginally lower (down 0.4% y/y).
- Sanitaryware and Faucetware together accounted for 47% and 40% of total revenues, respectively while project sales accounted for 39% and maintained a healthy momentum.
- Higher input costs, led to a fall in gross profit by 3.7% y/y to Rs2.4bn and margin contraction of 172bps y/y to 50.7%.
- Lower gross margin coupled with higher employee expense led to fall in EBITDA by 3.5% y/y to Rs671m, while margins were down just 44bps y/y to 13.8%. This was despite lower other expenses.
- Lower operating profits led a steep decline in PAT by 16.8% y/y to Rs566m, with PAT margin contracting 228bps y/y to 11.6%.
- Net working capital days stood at 29 vs 25 days in H1 FY25. Inventory/ receivable days were up by 2 days each to 24/42. Payable days were same at 37.

### **Q2 FY26 - Concall Key Takeaways**

Margins hold amid cost pressure, retail recovery awaited amidst growing B2B share

#### ■ Quarterly Revenue-mix

- Segment-wise: Sanitaryware/faucetware/tiles/wellness were at 47/40/11/2%.
- Category-wise: Premium/mid/entry-level product contributed 42/36/22% to total sales.
- Region-wise. Tier-I/II/III markets accounted for 36/23/41% of total sales.

#### ■ Project (B2B) Sales

- o B2B Segment (39% of Total Sales): saw healthy traction, aided by steady order inflows from real estate sector and sustained construction activities. Continued benefit from a strong brand equity, execution reliability and deep relationships across developer ecosystems enabled the company to participate in larger and more complex projects.
- **Project Sales:** Expected to remain at the current level of 39-40% in FY26 due to visible green shoots in retail environment.
- Retail: Continued to see subdued demand since past two years. While
  the exact timing of a broad-based retail recovery is still evolving, the
  management is optimistic of long-term growth of the industry.

#### ■ Segmental Highlights

- Sanitaryware. Revenue grew 1.4% y/y in Q2 FY26 (up 0.6% y/y in H1 FY26), supported by stable demand scenario.
- Faucetware. Revenue fell 3.5% y/y in Q2 FY26 (up 3.5% y/y in H1 FY26) due to high base effect which was driven by price hike implemented then due to rising prices of brass. With no price revision taken in the current FY, sales volume have remained healthy.
- o **Tiles.** Revenue grew 3.1% y/y in Q2 FY26 (up 4% y/y in H1 FY26).
- **Wellness.** Revenue grew 3.2% y/y in Q2 FY26 (up 8.2% y/y in H1 FY26).

#### Costs

- O Input Cost: Brass cost grew to Rs590-600/kg last year and remained stable thereafter. As of Nov'25, the brass prices have again increased to Rs620-630/kg. The company is partially offsetting these rises through improved operational efficiency and other cost optimisation initiatives across categories.
- o **Gas Cost (3.6% of Revenue):** The weighted average cost stood at Rs33.79/cu. mtr vs. Rs33.95/cu. mtr in Q2 FY25 (lower than industry average). Gas consumption: 80/20% from GAIL/Sabarmati.
- **Employee Cost:** The management is anticipating a wage increase of 7-8% in FY26.
- Capex: The management has committed an outlay of Rs230m, primarily for maintenance and strengthening brand presence and retail footprint.

#### **■** Business Performance

- o Capacity Utilisation for Sanitaryware/faucetware stood at 85/97%.
- Lower PAT: Lower PAT (down 16.8% y/y) was due to deferred tax income recognized in the previous year arising from a change in the capital gain tax rate on long-term investments. The current year's figures reflect normal operations without this one-time tax impact.
- WC Management: Inventory days rose from 80 to 83, receivable days rose from 30 to 33 days, while payable days remained stable at 39. Thus NWC days rose from 72 to 77.
- o Cash Balance: The cash balance stood at Rs7.4bn as on Sep'25.
- o **New launches** accounted for 33% of total sales in Q2 FY26.
- Cost Optimisation: Cera has taken steps to minimise promotional spend and cost/unit in Sanitaryware & Faucetware segments.
- Distribution Management System: Over 200 dealers were onboarded under this new initiative. This system offers a better visibility of secondary sales, dealer-wise inventory, retail coverage, and track market movement and support faster decision making.

#### ■ Strategic Initiatives

- Senator: As the luxury segment has been growing quite well (which CERA did not have a strong presence), it came up with luxury brand, *Senator*. The company is on track to achieve its FY26 flagship rollout target of 45-50 stores with 28 stores already operational till date.
- Polipluz: Currently, the products are distributed through 38/650 distributors/dealers. It targets to expand this 100/2,000 by Mar'26. Campaigns are underway to establish presence in Tier-III/IV markets.


#### ■ Other Highlights


- o **Tailwinds:** Continued formalisation in the industry, rising consumer aspiration, urban redevelopment and housing programmes, and sanitation initiatives alongside policy measures i.e., GST cut.
- Outlook: While the management is cautiously optimistic of demand recovery in H2 FY26, it is confident speed and scale led by ongoing investment in brands, channel and new markets.
- **Divestment:** In order to focus on core business, it exited its two subsidiaries: Packart Packaging and Race Polymer Arts in Sep'25 Rs187.5m and recorded a profit on sale of Rs55.4bn in other income.

#### ■ Growth Guidance

- o It expects to grow 10-12% in H2 to record 7-8% growth in FY26.
- o It expects Faucetware segment to grow by 8-10% in by FY26.
- o **Senator and Polipluz:** The management expects Rs400-450m revenue contribution in FY26 and targets Rs1.5bn revenue by FY27, and expects 20-22/25% margin in Senator/Polipluz. It will spend Rs100-120m on branding in FY26, which will rise in FY27. Further, employee cost is seen at ∼Rs140-150m in FY26.
- Gross and Operating Margin: The management pegs gross margin at 52-55%. Further, expecting improved volume in H2, operating margin for FY26 is seen at 14.5-15%.


### Story in Charts


















Source: Company, Anand Rathi Research










### **Outlook & Valuations**

Management is optimistic of recovery in H2 FY26 and is aiming at 7-8% growth for FY26. Volume recovery will aid achieving an operating margin of 14.5-15%. The company continues to focus on brand building, product innovation and operational efficiency.

We expect 8.9%/11.8% revenue/earnings CAGR over FY25-28. We retain our Buy recommendation on the stock with a 12-mth TP of Rs8443, 35x FY27e/FY28e average EPS (from Rs8,956 earlier).

Fig 18 - Change in estimates

		Earlier			Revised		Variance (%)		
(Rs m)	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e	FY26	FY27	FY28
Revenue	20,905	23,562	27,338	20,310	22,004	24,885	(2.8)	(6.6)	(9.0)
EBITDA	3,332	3,829	4,699	3,015	3,438	4,160	(9.5)	(10.2)	(11.5)
EBITDA Margin (%)	15.9	16.3	17.2	14.8	15.6	16.7	(109)	(63)	(47)
PAT	2,564	2,960	3,640	2,371	2,762	3,461	(7.5)	(6.7)	(4.9)
EPS (Rs)	198.8	229.5	282.3	183.8	214.1	268.4	(7.5)	(6.7)	(4.9)
Source: Anand Rathi Rese	arch								





### Risks


- Slowdown in economy activities leading to demand slowdown.
- Delay in expected pickup in retail demand.
- Under-absorption of overheads.
- Higher input cost.
- Increased competitive intensity.

#### **Appendix**

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

#### Important Disclosures on subject companies Rating and Target Price History (as of 24 November 2025)



#### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (Top 100 companies)	>15%	0-15%	<0%	
Mid Caps (101st-250th company)	>20%	0-20%	<0%	
Small Caps (251st company onwards)	>25%	0-25%	<0%	

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL),Multi Commodity Exchange of India Limited (MCX),National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

#### NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2025. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000 Grievance officer: Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.